Fulgent Genetics (FLGT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Fulgent Genetics (FLGT) do?
Fulgent Genetics Inc (FLGT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells clinical genomic sequencing, specialized anatomic pathology, and molecular diagnostic tests to medical providers. The business runs genetic testing, specialized cancer pathology, and drug development on proprietary software systems. It is worth $692.33M on the market and sold $329.68M over the last year.
- Market cap
- $692.33M
- P/E ratio
- None (reported a loss)
- Annual sales
- $329.68M
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 18, 2026
Brands and businesses behind FLGT
- Inform Diagnostics: Provides anatomic pathology laboratory testing to medical practices, earning revenue from medical billing and patient fees.
- CSI Laboratories: Offers specialized cancer diagnostic services to hospitals and clinics, earning revenue from laboratory testing fees.
- Picture Genetics: Sells consumer at-home genetic screening kits online, earning revenue directly from customer purchases.
FLGT’s flags, in plain English
Each flag is a number from Fulgent Genetics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 5.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Insiders Hold
Insiders own 36% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -27.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about FLGT
How big is Fulgent Genetics?
Fulgent Genetics’ market cap is $692.33M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $329.68M: what customers paid the company over the last year, before any costs.
What is FLGT’s P/E ratio?
FLGT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with FLGT?
Testing revenue remains exposed to commercial insurers and government payers that reduce or deny coverage for genetic panels. That is one risk on Fulgent Genetics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Fulgent Genetics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FLGT’s filings on SEC.gov. The Margin Monkey is research, not advice.
